Get the Stockscreener App
23.65
4.44%
-1.10
After Hours:
23.64
-0.010
-0.04%
Overview
News
Price History
Option Chain
Why FMS Down?
Discussions
Forecast
Stock Split
Dividend History
Fresenius Medical Care Ag Adr stock is traded at $23.65, with a volume of 445.02K.
It is down -4.44% in the last 24 hours and down -2.23% over the past month.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three quarters of sales while the balance is generated from medical technology products that enable dialysis treatments.
See More
Previous Close:
$24.75
Open:
$23.74
24h Volume:
445.02K
Relative Volume:
1.42
Market Cap:
$14.48B
Revenue:
$20.87B
Net Income/Loss:
$715.14M
P/E Ratio:
19.37
EPS:
1.2209
Net Cash Flow:
$1.67B
1W Performance:
-0.71%
1M Performance:
-2.23%
6M Performance:
+18.01%
1Y Performance:
+24.67%
1-Day Range:
$23.51
$23.85
1-Week Range:
$23.50
$25.16
52-Week Range:
$17.93
$25.96
Fresenius Medical Care Ag Adr Stock (FMS) Company Profile
Name
Fresenius Medical Care Ag Adr
Sector
Industry
Phone
-
Address
-
Compare FMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FMS
Fresenius Medical Care Ag Adr
|
23.65 | 14.48B | 20.87B | 715.14M | 1.67B | 1.2209 |
|
HCA
Hca Healthcare Inc
|
335.01 | 83.86B | 70.60B | 5.76B | 5.64B | 21.97 |
|
DVA
Davita Inc
|
140.03 | 12.07B | 12.67B | 827.68M | 1.42B | 9.27 |
|
THC
Tenet Healthcare Corp
|
121.81 | 11.79B | 20.97B | 3.13B | 2.39B | 31.21 |
|
UHS
Universal Health Services Inc
|
174.80 | 11.66B | 15.42B | 1.03B | 956.84M | 15.02 |
Fresenius Medical Care Ag Adr Stock (FMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-06-24 | Initiated | Berenberg | Buy |
| Jan-08-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-24-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-17-23 | Upgrade | Societe Generale | Hold → Buy |
| Aug-14-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Resumed | Citigroup | Neutral |
| Jul-12-23 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | Bernstein | Mkt Perform |
| Jan-03-23 | Downgrade | Jefferies | Buy → Underperform |
| Oct-26-22 | Downgrade | Deutsche Bank | Hold → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-27-22 | Upgrade | Jefferies | Underperform → Buy |
| Feb-11-22 | Downgrade | Jefferies | Hold → Underperform |
| Nov-23-21 | Initiated | HSBC Securities | Hold |
| Nov-11-21 | Upgrade | Jefferies | Underperform → Hold |
| Feb-04-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-03-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| May-20-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-21-20 | Upgrade | Jefferies | Hold → Buy |
| Jun-20-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-26-18 | Upgrade | UBS | Neutral → Buy |
| Aug-28-18 | Upgrade | HSBC Securities | Hold → Buy |
| Jul-05-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-04-18 | Upgrade | UBS | Sell → Neutral |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-01-16 | Reiterated | RBC Capital Mkts | Sector Perform |
| Sep-06-16 | Upgrade | Citigroup | Neutral → Buy |
| Jul-08-16 | Upgrade | Jefferies | Underperform → Hold |
| Jan-04-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-04-15 | Reiterated | RBC Capital Mkts | Sector Perform |
| Sep-03-15 | Upgrade | Goldman | Neutral → Buy |
| Aug-13-15 | Downgrade | Societe Generale | Buy → Hold |
| Jul-31-15 | Reiterated | RBC Capital Mkts | Sector Perform |
| Aug-02-13 | Reiterated | Feltl & Co. | Hold |
| Jan-14-13 | Upgrade | HSBC Securities | Neutral → Overweight |
View All
Fresenius Medical Care Ag Adr Stock (FMS) Latest News
From Kidney Failure to Fresenius Medical Care Employee: A Transplant Story - Fresenius Medical Care
Dialysis Nurse Becomes Kidney Patient After COVID-19 - Fresenius Medical Care
What Sets Our Nurses Apart - Fresenius Medical Care
A Transplant Story: Patient Care Technician Gives Dialysis Patient the Gift of Life - Fresenius Medical Care
Fresenius Medical Care plans bond sale stabilization By Investing.com - Investing.com South Africa
The Zacks Analyst Blog Highlights Reddit, Ubiquiti And Fresenius Medical Care AG - Barchart.com
Fresenius Medical Care plans bond sale stabilization - Investing.com
Predicting Population Trends in Kidney Health Using Advanced Mathematical Modeling - Fresenius Medical Care
Dry Bicarbonate Concentrate Bags for Hemodialysis in the State of São Paulo in Brazil - Fresenius Medical Care
Fresenius Economic Profit Margins Should Rise Along With Improvement in Both Operating Segments - Morningstar
Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum - Fresenius Medical Care
Kidney Disease: Evolving the Standard of Care - Fresenius Medical Care
Sanctuary Advisors LLC Acquires New Holdings in Fresenius Medical Care AG (NYSE:FMS) - MarketBeat
Fresenius Medical Care ADR earnings missed by $0.26, revenue fell short of estimates - Investing.com South Africa
Fresenius Medical Care published form 20-F for the fiscal year 2024 - Fresenius Medical Care
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Fresenius Medical Care sees strong Q4 2024 growth - Investing.com
Fresenius Medical Care Q4 earnings miss estimates, stock edges higher - Investing.com
Dialysis firm FMC beats profit estimates in fourth quarter By Reuters - Investing.com
Annual Press Conference 2025 - Fresenius Medical Care
Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025 - Fresenius Medical Care
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics - Fresenius Medical Care
Growing Stronger Together: Embracing Diversity - Fresenius Medical Care
Corporate Citizenship - Fresenius Medical Care
Fresenius Medical Care: A 'Buy' Going Into 2025 (NYSE:FMS) - Seeking Alpha
Virtual reality as the next step in patient empowerment - Fresenius Medical Care
Coming Back Home: Dr. Len Usvyat Appointed as the Next Head of the Renal Research Institute - Fresenius Medical Care
17,962 miles halfway around the world - Fresenius Medical Care
“How can we improve and speed up medical decisions?” - Fresenius Medical Care
20 years creating a future worth living - Fresenius Medical Care
Overcoming challenges and seizing opportunities - Fresenius Medical Care
When Maria struck — One year after the hurricane - Fresenius Medical Care
Our Way Forward - Fresenius Medical Care
Corporate Movie 2021 - Fresenius Medical Care
Our way forward - Fresenius Medical Care
The Next Level of Renal Care - Fresenius Medical Care
Me and my four kidneys - Fresenius Medical Care
A superhero wins over Asia-Pacific - Fresenius Medical Care
Joining forces for a better future - Fresenius Medical Care
Improving dialysis through knowledge sharing in Southeast Asia - Fresenius Medical Care
A truly miraculous story – 50 years on dialysis - Fresenius Medical Care
Smart Companion for an active lifestyle - Fresenius Medical Care
The future is purple - Fresenius Medical Care
Regenerative Medicine: The road to healing - Fresenius Medical Care
The Life Long Learner - Fresenius Medical Care
Africa changing times - Fresenius Medical Care
A journey of friendship: How home hemodialysis changed Annalese's life - Fresenius Medical Care
Health Equity in Kidney Care: Interview with Lorien Dalrymple, MD, MPH - Fresenius Medical Care
20 years Fresenius Medical Care - Fresenius Medical Care
Making transplants safer and more widely available - Fresenius Medical Care
Remuneration of the Supervisory Board - Fresenius Medical Care
Fresenius Medical Care Ag Adr Stock (FMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):